Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer-Reference-Cited by-同舟云学术

Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer

Published:2023-12 Issue: Volume: Page:
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Buteau James P.^ORCID,Moon Daniel,Fahey Michael T.,Roberts Matthew J.,Thompson James,Murphy Declan G.,Papa Nathan,Mitchell Catherine,De Abreu Lourenco Richard,Dhillon Haryana M.,Kasivisvanathan Veeru,Francis Roslyn J.,Stricker Phillip,Agrawal Shihka,O'Brien Jonathan,McVey Aoife,Sharma Gaurav,Levy Sidney,Ayati Narjess,Nguyen Andrew,Lee Su-Faye,Pattison David A.,Sivaratnam Dinesh,Frydenberg Mark,Du Yang,Titus Jehan,Lee Sze-Ting,Ischia Joseph,Jack Greg,Hofman Michael S.,Emmett Louise

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference33 articles.

1. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study;Ahmed;Lancet,2017

2. MRI-targeted or standard biopsy for prostate-cancer diagnosis;Kasivisvanathan;N Engl J Med,2018

3. PRECISION delivers on the PROMIS of mpMRI in early detection;Nzenza;Nat Rev Urol,2018

4. Interobserver reproducibility of the PI-RADS version 2 lexicon: a multicenter study of six experienced prostate radiologists;Rosenkrantz;Radiology,2016

5. Performance and inter-observer variability of prostate MRI (PI-RADS version 2) outside high-volume centres;Kohestani;Scand J Urol,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Re: First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma;European Urology;2024-09

2. PSMA-based therapeutics for prostate cancer;Expert Opinion on Pharmacotherapy;2024-07-02

3. Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.11.008;European Urology Oncology;2024-04

4. Key learnings from concordant systematic biopsies in prostate‐specific membrane antigen positron emission tomography/computed tomography‐guided prostate biopsies: Enhancing targeting accuracy;The Prostate;2024-03-20